Further studies showed TGFB pathway activation in tumor microenvironmental fibroblasts reduces the infiltration of T cells into the tumor, thereby inhibiting the therapeutic efficacy of PD-L1 inhibition. This evidence concerns the gene CD274 and neoplasm.